Neurology Clinical Trial - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510241444

Publication Date:

October 14, 2024

Pages:

157

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Neurology Clinical Trial was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Neurology Clinical Trial was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neurology Clinical Trial was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Neurology Clinical Trial was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Neurology Clinical Trial include BrainStorm Cell Therapeutics, Opexa Therapeutics, Caladrius Biosciences, U.S. Stem Cell, Lonza, Bristol Myers Squibb, Corning Incorporated, Vericel Corporation and Catalent, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurology Clinical Trial, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neurology Clinical Trial by region & country, by Type, and by Application.
The Neurology Clinical Trial market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurology Clinical Trial.
麻豆原创 Segmentation
By Company
BrainStorm Cell Therapeutics
Opexa Therapeutics
Caladrius Biosciences
U.S. Stem Cell
Lonza
Bristol Myers Squibb
Corning Incorporated
Vericel Corporation
Catalent
Lineage Cell Therapeutics
Castle Creek Biosciences
Sangamo Therapeutics
Novartis
Holostem Terapie Avanzate S.R.L
Pharmicell
Tego Science
Autolus therapeutics
Bayer AG
Sartorius AG
Daiichi Sankyo
Takeda Pharmaceutical Company
Sumitomo Chemical Co
Segment by Type:
Bone Marrow
Epidermis
Mesenchymal Stem Cells
Haematopoietic Stem Cells
Chondrocytes
Segment by Application
Neurodegenerative Disorders
Cardiovascular Disorders
Orthopedics
Wound Healing
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neurology Clinical Trial manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Neurology Clinical Trial in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Neurology Clinical Trial in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Neurology Clinical Trial Product Introduction
1.2 Global Neurology Clinical Trial 麻豆原创 Size Forecast
1.3 Neurology Clinical Trial 麻豆原创 Trends & Drivers
1.3.1 Neurology Clinical Trial Industry Trends
1.3.2 Neurology Clinical Trial 麻豆原创 Drivers & Opportunity
1.3.3 Neurology Clinical Trial 麻豆原创 Challenges
1.3.4 Neurology Clinical Trial 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neurology Clinical Trial Players Revenue Ranking (2023)
2.2 Global Neurology Clinical Trial Revenue by Company (2019-2024)
2.3 Key Companies Neurology Clinical Trial Manufacturing Base Distribution and Headquarters
2.4 Key Companies Neurology Clinical Trial Product Offered
2.5 Key Companies Time to Begin Mass Production of Neurology Clinical Trial
2.6 Neurology Clinical Trial 麻豆原创 Competitive Analysis
2.6.1 Neurology Clinical Trial 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Neurology Clinical Trial Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurology Clinical Trial as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Bone Marrow
3.1.2 Epidermis
3.1.3 Mesenchymal Stem Cells
3.1.4 Haematopoietic Stem Cells
3.1.5 Chondrocytes
3.2 Global Neurology Clinical Trial Sales Value by Type
3.2.1 Global Neurology Clinical Trial Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neurology Clinical Trial Sales Value, by Type (2019-2030)
3.2.3 Global Neurology Clinical Trial Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Neurodegenerative Disorders
4.1.2 Cardiovascular Disorders
4.1.3 Orthopedics
4.1.4 Wound Healing
4.1.5 Other
4.2 Global Neurology Clinical Trial Sales Value by Application
4.2.1 Global Neurology Clinical Trial Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neurology Clinical Trial Sales Value, by Application (2019-2030)
4.2.3 Global Neurology Clinical Trial Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Neurology Clinical Trial Sales Value by Region
5.1.1 Global Neurology Clinical Trial Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neurology Clinical Trial Sales Value by Region (2019-2024)
5.1.3 Global Neurology Clinical Trial Sales Value by Region (2025-2030)
5.1.4 Global Neurology Clinical Trial Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Neurology Clinical Trial Sales Value, 2019-2030
5.2.2 North America Neurology Clinical Trial Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Neurology Clinical Trial Sales Value, 2019-2030
5.3.2 Europe Neurology Clinical Trial Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Neurology Clinical Trial Sales Value, 2019-2030
5.4.2 Asia Pacific Neurology Clinical Trial Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Neurology Clinical Trial Sales Value, 2019-2030
5.5.2 South America Neurology Clinical Trial Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Neurology Clinical Trial Sales Value, 2019-2030
5.6.2 Middle East & Africa Neurology Clinical Trial Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neurology Clinical Trial Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neurology Clinical Trial Sales Value
6.3 United States
6.3.1 United States Neurology Clinical Trial Sales Value, 2019-2030
6.3.2 United States Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neurology Clinical Trial Sales Value, 2019-2030
6.4.2 Europe Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neurology Clinical Trial Sales Value, 2019-2030
6.5.2 China Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neurology Clinical Trial Sales Value, 2019-2030
6.6.2 Japan Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neurology Clinical Trial Sales Value, 2019-2030
6.7.2 South Korea Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neurology Clinical Trial Sales Value, 2019-2030
6.8.2 Southeast Asia Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neurology Clinical Trial Sales Value, 2019-2030
6.9.2 India Neurology Clinical Trial Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neurology Clinical Trial Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 BrainStorm Cell Therapeutics
7.1.1 BrainStorm Cell Therapeutics Profile
7.1.2 BrainStorm Cell Therapeutics Main Business
7.1.3 BrainStorm Cell Therapeutics Neurology Clinical Trial Products, Services and Solutions
7.1.4 BrainStorm Cell Therapeutics Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.1.5 BrainStorm Cell Therapeutics Recent Developments
7.2 Opexa Therapeutics
7.2.1 Opexa Therapeutics Profile
7.2.2 Opexa Therapeutics Main Business
7.2.3 Opexa Therapeutics Neurology Clinical Trial Products, Services and Solutions
7.2.4 Opexa Therapeutics Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.2.5 Opexa Therapeutics Recent Developments
7.3 Caladrius Biosciences
7.3.1 Caladrius Biosciences Profile
7.3.2 Caladrius Biosciences Main Business
7.3.3 Caladrius Biosciences Neurology Clinical Trial Products, Services and Solutions
7.3.4 Caladrius Biosciences Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.3.5 U.S. Stem Cell Recent Developments
7.4 U.S. Stem Cell
7.4.1 U.S. Stem Cell Profile
7.4.2 U.S. Stem Cell Main Business
7.4.3 U.S. Stem Cell Neurology Clinical Trial Products, Services and Solutions
7.4.4 U.S. Stem Cell Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.4.5 U.S. Stem Cell Recent Developments
7.5 Lonza
7.5.1 Lonza Profile
7.5.2 Lonza Main Business
7.5.3 Lonza Neurology Clinical Trial Products, Services and Solutions
7.5.4 Lonza Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.5.5 Lonza Recent Developments
7.6 Bristol Myers Squibb
7.6.1 Bristol Myers Squibb Profile
7.6.2 Bristol Myers Squibb Main Business
7.6.3 Bristol Myers Squibb Neurology Clinical Trial Products, Services and Solutions
7.6.4 Bristol Myers Squibb Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.6.5 Bristol Myers Squibb Recent Developments
7.7 Corning Incorporated
7.7.1 Corning Incorporated Profile
7.7.2 Corning Incorporated Main Business
7.7.3 Corning Incorporated Neurology Clinical Trial Products, Services and Solutions
7.7.4 Corning Incorporated Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.7.5 Corning Incorporated Recent Developments
7.8 Vericel Corporation
7.8.1 Vericel Corporation Profile
7.8.2 Vericel Corporation Main Business
7.8.3 Vericel Corporation Neurology Clinical Trial Products, Services and Solutions
7.8.4 Vericel Corporation Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.8.5 Vericel Corporation Recent Developments
7.9 Catalent
7.9.1 Catalent Profile
7.9.2 Catalent Main Business
7.9.3 Catalent Neurology Clinical Trial Products, Services and Solutions
7.9.4 Catalent Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.9.5 Catalent Recent Developments
7.10 Lineage Cell Therapeutics
7.10.1 Lineage Cell Therapeutics Profile
7.10.2 Lineage Cell Therapeutics Main Business
7.10.3 Lineage Cell Therapeutics Neurology Clinical Trial Products, Services and Solutions
7.10.4 Lineage Cell Therapeutics Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.10.5 Lineage Cell Therapeutics Recent Developments
7.11 Castle Creek Biosciences
7.11.1 Castle Creek Biosciences Profile
7.11.2 Castle Creek Biosciences Main Business
7.11.3 Castle Creek Biosciences Neurology Clinical Trial Products, Services and Solutions
7.11.4 Castle Creek Biosciences Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.11.5 Castle Creek Biosciences Recent Developments
7.12 Sangamo Therapeutics
7.12.1 Sangamo Therapeutics Profile
7.12.2 Sangamo Therapeutics Main Business
7.12.3 Sangamo Therapeutics Neurology Clinical Trial Products, Services and Solutions
7.12.4 Sangamo Therapeutics Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.12.5 Sangamo Therapeutics Recent Developments
7.13 Novartis
7.13.1 Novartis Profile
7.13.2 Novartis Main Business
7.13.3 Novartis Neurology Clinical Trial Products, Services and Solutions
7.13.4 Novartis Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.13.5 Novartis Recent Developments
7.14 Holostem Terapie Avanzate S.R.L
7.14.1 Holostem Terapie Avanzate S.R.L Profile
7.14.2 Holostem Terapie Avanzate S.R.L Main Business
7.14.3 Holostem Terapie Avanzate S.R.L Neurology Clinical Trial Products, Services and Solutions
7.14.4 Holostem Terapie Avanzate S.R.L Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.14.5 Holostem Terapie Avanzate S.R.L Recent Developments
7.15 Pharmicell
7.15.1 Pharmicell Profile
7.15.2 Pharmicell Main Business
7.15.3 Pharmicell Neurology Clinical Trial Products, Services and Solutions
7.15.4 Pharmicell Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.15.5 Pharmicell Recent Developments
7.16 Tego Science
7.16.1 Tego Science Profile
7.16.2 Tego Science Main Business
7.16.3 Tego Science Neurology Clinical Trial Products, Services and Solutions
7.16.4 Tego Science Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.16.5 Tego Science Recent Developments
7.17 Autolus therapeutics
7.17.1 Autolus therapeutics Profile
7.17.2 Autolus therapeutics Main Business
7.17.3 Autolus therapeutics Neurology Clinical Trial Products, Services and Solutions
7.17.4 Autolus therapeutics Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.17.5 Autolus therapeutics Recent Developments
7.18 Bayer AG
7.18.1 Bayer AG Profile
7.18.2 Bayer AG Main Business
7.18.3 Bayer AG Neurology Clinical Trial Products, Services and Solutions
7.18.4 Bayer AG Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.18.5 Bayer AG Recent Developments
7.19 Sartorius AG
7.19.1 Sartorius AG Profile
7.19.2 Sartorius AG Main Business
7.19.3 Sartorius AG Neurology Clinical Trial Products, Services and Solutions
7.19.4 Sartorius AG Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.19.5 Sartorius AG Recent Developments
7.20 Daiichi Sankyo
7.20.1 Daiichi Sankyo Profile
7.20.2 Daiichi Sankyo Main Business
7.20.3 Daiichi Sankyo Neurology Clinical Trial Products, Services and Solutions
7.20.4 Daiichi Sankyo Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.20.5 Daiichi Sankyo Recent Developments
7.21 Takeda Pharmaceutical Company
7.21.1 Takeda Pharmaceutical Company Profile
7.21.2 Takeda Pharmaceutical Company Main Business
7.21.3 Takeda Pharmaceutical Company Neurology Clinical Trial Products, Services and Solutions
7.21.4 Takeda Pharmaceutical Company Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.21.5 Takeda Pharmaceutical Company Recent Developments
7.22 Sumitomo Chemical Co
7.22.1 Sumitomo Chemical Co Profile
7.22.2 Sumitomo Chemical Co Main Business
7.22.3 Sumitomo Chemical Co Neurology Clinical Trial Products, Services and Solutions
7.22.4 Sumitomo Chemical Co Neurology Clinical Trial Revenue (US$ Million) & (2019-2024)
7.22.5 Sumitomo Chemical Co Recent Developments
8 Industry Chain Analysis
8.1 Neurology Clinical Trial Industrial Chain
8.2 Neurology Clinical Trial Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neurology Clinical Trial Sales Model
8.5.2 Sales Channel
8.5.3 Neurology Clinical Trial Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

BrainStorm Cell Therapeutics
Opexa Therapeutics
Caladrius Biosciences
U.S. Stem Cell
Lonza
Bristol Myers Squibb
Corning Incorporated
Vericel Corporation
Catalent
Lineage Cell Therapeutics
Castle Creek Biosciences
Sangamo Therapeutics
Novartis
Holostem Terapie Avanzate S.R.L
Pharmicell
Tego Science
Autolus therapeutics
Bayer AG
Sartorius AG
Daiichi Sankyo
Takeda Pharmaceutical Company
Sumitomo Chemical Co

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.